Similar articles for PMID: 22690007

Year	Number of Results
1994	1
2005	1
2009	1
2011	3
2012	10
2013	4
2014	4
2015	11
2016	11
2017	11
2018	16
2019	22
2020	14
2021	6
2022	4
2023	1
2024	0

1

Africa struggles to improve drug safety.

Appiah B. Appiah B. CMAJ. 2012 Jul 10;184(10):E533-4. doi: 10.1503/cmaj.109-4199. Epub 2012 Jun 11. CMAJ. 2012. PMID: 22690007 Free PMC article. No abstract available.

2

Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.

Jusot V, Chimimba F, Dzabala N, Menang O, Cole J, Gardiner G, Ofori-Anyinam O, Oladehin O, Sambakunsi C, Kawaye M, Stegmann JU, Guerra Mendoza Y. Jusot V, et al. Drug Saf. 2020 Jun;43(6):583-593. doi: 10.1007/s40264-020-00925-4. Drug Saf. 2020. PMID: 32239447 Free PMC article.

3

Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records.

Liu F, Jagannatha A, Yu H. Liu F, et al. Drug Saf. 2019 Jan;42(1):95-97. doi: 10.1007/s40264-018-0766-8. Drug Saf. 2019. PMID: 30649734 Free PMC article. No abstract available.

4

Report of Adverse Events in Colombia: A Successful Case.

Moreno-Mattar O, Ramírez R, Alvarado A, Sierra F, Guzmán J. Moreno-Mattar O, et al. Curr Drug Saf. 2019;14(1):53-56. doi: 10.2174/1574886313666181109150648. Curr Drug Saf. 2019. PMID: 30411692

5

Canada's Adverse Drug Reaction Reporting System: A Failing Grade.

Rawson NS. Rawson NS. J Popul Ther Clin Pharmacol. 2015;22(2):e167-72. Epub 2015 Sep 11. J Popul Ther Clin Pharmacol. 2015. PMID: 26590356

6

Pharmacovigilance Programme of India: Recent developments and future perspectives.

Kalaiselvan V, Thota P, Singh GN. Kalaiselvan V, et al. Indian J Pharmacol. 2016 Nov-Dec;48(6):624-628. doi: 10.4103/0253-7613.194855. Indian J Pharmacol. 2016. PMID: 28066097 Free PMC article. Review.

7

Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations.

Ribeiro A, Lima S, Zampieri ME, Peinado M, Figueras A. Ribeiro A, et al. Expert Opin Drug Saf. 2017 Dec;16(12):1329-1334. doi: 10.1080/14740338.2017.1369525. Epub 2017 Aug 23. Expert Opin Drug Saf. 2017. PMID: 28817316

8

Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.

Barry A, Olsson S, Minzi O, Bienvenu E, Makonnen E, Kamuhabwa A, Oluka M, Guantai A, Bergman U, van Puijenbroek E, Gurumurthy P, Aklillu E. Barry A, et al. Drug Saf. 2020 Apr;43(4):339-350. doi: 10.1007/s40264-019-00898-z. Drug Saf. 2020. PMID: 31919794 Free PMC article.

9

Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases.

Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, Cracowski JL. Khouri C, et al. J Clin Epidemiol. 2021 Jun;134:14-21. doi: 10.1016/j.jclinepi.2021.01.015. Epub 2021 Jan 26. J Clin Epidemiol. 2021. PMID: 33508405

10

Adverse drug reaction reporting in institutions across six Chinese provinces: a cross-sectional study.

Zhang X, Niu R, Feng B, Guo J, Liu Y, Liu X. Zhang X, et al. Expert Opin Drug Saf. 2019 Jan;18(1):59-68. doi: 10.1080/14740338.2018.1486820. Epub 2018 Jun 14. Expert Opin Drug Saf. 2019. PMID: 29883236

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

106 results

Results by year